Exciting times at Candel Therapeutics Written by Paul Peter Tak on June 28, 2021. Posted in Projects. 1 Comment Erasing cancer, reviving oncolytic virus, treating a rare neuromuscular condition: Here’s what you need to know about the 5 new biotechs filing for IPOs
The results of this first-in-human study of CAN-3110 demonstrate a median overall survival that was substantially longer than the six to nine months typically observed in recurrent high-grade glioma as well as a favorable safety profile. Written by Paul Peter Tak on June 4, 2021. Posted in Projects. Leave a Comment https://www.businesswire.com/news/home/20210604005138/en/Candel-Therapeutics-Announces-Data-from-Phase-1-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-2021-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting
